JP2008534541A - 置換1,2−エチレンジアミン、前記化合物を含む薬物、それらの使用及びそれらの製造方法 - Google Patents

置換1,2−エチレンジアミン、前記化合物を含む薬物、それらの使用及びそれらの製造方法 Download PDF

Info

Publication number
JP2008534541A
JP2008534541A JP2008503415A JP2008503415A JP2008534541A JP 2008534541 A JP2008534541 A JP 2008534541A JP 2008503415 A JP2008503415 A JP 2008503415A JP 2008503415 A JP2008503415 A JP 2008503415A JP 2008534541 A JP2008534541 A JP 2008534541A
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
heteroaryl
group
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008503415A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008534541A5 (enExample
Inventor
クリシュティアン アイクマイアー
クラウス フューフス
シュテファン ペーターズ
ツィオセック コルネリア ドルナー
ニクラス ハイネ
ザンドラ ハントシュー
クラウス クリンダー
マルクス コシュトカ
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2008534541A publication Critical patent/JP2008534541A/ja
Publication of JP2008534541A5 publication Critical patent/JP2008534541A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0821Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008503415A 2005-03-30 2006-03-27 置換1,2−エチレンジアミン、前記化合物を含む薬物、それらの使用及びそれらの製造方法 Pending JP2008534541A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05006939 2005-03-30
PCT/EP2006/002769 WO2006103038A1 (en) 2005-03-30 2006-03-27 Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture

Publications (2)

Publication Number Publication Date
JP2008534541A true JP2008534541A (ja) 2008-08-28
JP2008534541A5 JP2008534541A5 (enExample) 2009-05-14

Family

ID=36545049

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008503415A Pending JP2008534541A (ja) 2005-03-30 2006-03-27 置換1,2−エチレンジアミン、前記化合物を含む薬物、それらの使用及びそれらの製造方法

Country Status (7)

Country Link
US (3) US7713961B2 (enExample)
EP (1) EP1866034A1 (enExample)
JP (1) JP2008534541A (enExample)
AR (1) AR056862A1 (enExample)
CA (1) CA2603404A1 (enExample)
TW (1) TW200716152A (enExample)
WO (1) WO2006103038A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009504614A (ja) * 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用化合物
JP2009504613A (ja) * 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用化合物

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006103038A1 (en) * 2005-03-30 2006-10-05 Boehringer Ingelheim International Gmbh Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture
EP1913017A1 (en) * 2005-08-03 2008-04-23 Boehringer Ingelheim International GmbH Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
US20100298278A1 (en) * 2005-08-11 2010-11-25 Christian Eickmeier Inhibitors of beta-secretase for the treatment of alzheimer's disease
EP1915352A1 (de) * 2005-08-11 2008-04-30 Boehringer Ingelheim International GmbH Verbindungen zur behandlung der alzheimer erkrankung
EP2349308A4 (en) 2008-10-10 2012-09-12 Purdue Research Foundation COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2376083A4 (en) 2008-11-20 2012-06-20 Purdue Research Foundation QUINAZOLIN-BASED BACE-1 INHIBITORS AND METHODS OF USE
WO2010065861A2 (en) * 2008-12-05 2010-06-10 Purdue Research Foundation Inhibitors of bace 1 and methods for treating alzheimer's disease
JP2013506713A (ja) * 2009-10-05 2013-02-28 コメンティス,インコーポレーテッド β−セクレターゼ活性を阻害するスルホンアミドピロリジン化合物及びその使用方法
WO2014036105A2 (en) * 2012-08-30 2014-03-06 Oklahoma Medical Research Foundation Inhibitors of memapsin 2 cleavage for the treatment of alzheimer's disease
US12018015B2 (en) 2021-06-18 2024-06-25 Aligos Therapeutics, Inc. Methods and compositions for targeting PD-L1
WO2023114365A1 (en) 2021-12-16 2023-06-22 Aligos Therapeutics, Inc. Methods and compositions for targeting pd-l1

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057721A2 (en) * 2002-01-04 2003-07-17 Elan Pharmaceuticals, Inc. Substituted amino carboxamides for the treatment of alzheimer's disease
WO2004029019A2 (en) * 2002-09-27 2004-04-08 Elan Pharmaceuticals, Inc. Compounds for the treatment of alzheimer’s disease
WO2004043916A1 (en) * 2002-11-12 2004-05-27 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005004802A2 (en) * 2003-06-30 2005-01-20 Merck & Co., Inc. N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ264143A (en) 1993-08-09 1996-11-26 Lilly Co Eli Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production
US7087399B1 (en) 1999-05-13 2006-08-08 Scios, Inc. β-secretase and modulation of β-secretase activity
AU5773500A (en) 1999-06-28 2001-01-31 Board Of Trustees Of The University Of Illinois, The Inhibitors of memapsin 2 and use thereof
US20050130941A1 (en) * 2001-06-08 2005-06-16 Heinrich Schostarez Methods of treating alzheimer's disease
WO2003032994A2 (de) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
US20050090449A1 (en) 2003-05-13 2005-04-28 Boehringer Ingelheim International Gmbh Novel statine derivatives for the treatment of Alzheimer's disease
JP2007538024A (ja) 2004-05-19 2007-12-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アミロイドベータペプチドのレベル変化に関連する疾患及び状態の治療方法及び新規エノールカルボキサミド化合物
WO2005113582A1 (en) 2004-05-22 2005-12-01 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease
WO2006050861A2 (en) 2004-11-10 2006-05-18 Boehringer Ingelheim International Gmbh Statine derivatives for the treatment of alzheimer's disease
WO2006050862A1 (en) 2004-11-10 2006-05-18 Boehringer Ingelheim International Gmbh Statine derivatives for the treatment of alzheimer's disease
WO2006103038A1 (en) * 2005-03-30 2006-10-05 Boehringer Ingelheim International Gmbh Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture
EP1913017A1 (en) 2005-08-03 2008-04-23 Boehringer Ingelheim International GmbH Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
EP1915352A1 (de) 2005-08-11 2008-04-30 Boehringer Ingelheim International GmbH Verbindungen zur behandlung der alzheimer erkrankung

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057721A2 (en) * 2002-01-04 2003-07-17 Elan Pharmaceuticals, Inc. Substituted amino carboxamides for the treatment of alzheimer's disease
WO2004029019A2 (en) * 2002-09-27 2004-04-08 Elan Pharmaceuticals, Inc. Compounds for the treatment of alzheimer’s disease
WO2004043916A1 (en) * 2002-11-12 2004-05-27 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005004802A2 (en) * 2003-06-30 2005-01-20 Merck & Co., Inc. N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009504614A (ja) * 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用化合物
JP2009504613A (ja) * 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用化合物

Also Published As

Publication number Publication date
US7713961B2 (en) 2010-05-11
US20090325940A1 (en) 2009-12-31
AR056862A1 (es) 2007-10-31
EP1866034A1 (en) 2007-12-19
CA2603404A1 (en) 2006-10-05
WO2006103038A1 (en) 2006-10-05
TW200716152A (en) 2007-05-01
US20060223759A1 (en) 2006-10-05
US20100204160A1 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
US20100204160A1 (en) Substituted 1,2-ethylenediamines, methods for preparing them and uses thereof
US9234000B2 (en) Benzylamine derivatives as inhibitors of plasma kallikrein
KR19980703151A (ko) 락탐-함유 히드록삼산 유도체, 그의 제조 그리고 매트릭스 메탈로프로테아제의 억제제로서의 그의 용도
JP5450407B2 (ja) 置換アミノ−キナゾリノン、前記化合物を含む薬物、それらの使用及び製造方法
SI9620120A (sl) Nove makrociklične spojine kot metaloproteazni inhibitorji
CA2323691A1 (en) Certain thiol inhibitors of endothelin-converting enzyme
JPH02256658A (ja) アミノ酸誘導体
JP2009504614A (ja) アルツハイマー病の治療用化合物
JP2009504612A (ja) アルツハイマー病の治療用化合物
JP2009504613A (ja) アルツハイマー病の治療用化合物
JP2009504611A (ja) アルツハイマー病の治療用β−セクレターゼインヒビター
JP2009503027A (ja) アルツハイマー病iiの治療のための置換エタン−1,2−ジアミン
NZ620271B2 (en) Benzylamine derivatives as inhibitors of plasma kallikrein
HK1197055B (en) Benzylamine derivatives as inhibitors of plasma kallikrein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120423